However, findings from the DESTINY-Breast04 (DB-04)5 trial demonstrated that T-DXd significantly improved both progression-free and overall survival in individuals with low expression of HER2, with the latter particularly remarkable in the context of metastatic disease. This evidence concerns the gene ERBB2 and metastatic neoplasm.